Former Eli Lilly execs donate $20 million to establish IU Health clinical institute
Two former Eli Lilly executives and their families will donate $20 million to IU Health Foundation — the largest philanthropic gift in the foundation's history — to establish the Institute for Clinical Innovation, a hub for groundbreaking disease detection and treatment.
IU Health will match the gift, bringing the total investment to $40 million shared between the health system and the medical school. The IU Health Foundation acts as the philanthropic arm of IU Health's statewide health care system.
Housed in the massive IU hospital complex under construction on the north side of downtown, the institute will accelerate the speed of medical research in Indiana and provide clinicians and researchers with more resources. IU Health leaders say they hope the investment will triple the number of patients in clinical trials. They hope to enroll 75,000 patients in clinical trials each year and within five years enroll 300,000 people in the Indiana Biobank initiative.
Indianapolis residents Sarah and John Lechleiter and Deborah and Randall Tobias partnered on the donation that will benefit patients across Indiana. Randall Tobias held the title of chair, president and CEO of Eli Lilly from 1993-2003, before he was nominated by President George W. Bush to lead the U.S. effort to fight against the global HIV/AIDS epidemic. John Lechleiter served as CEO of the pharmaceutical giant from 2008-2017 before handing over the reins to current CEO Dave Ricks.
'Our families share a commitment to advancing the future of healthcare for our Hoosier neighbors,' the Tobiases and Lechleiters said in a joint statement. 'This gift will support IU Health and IU School of Medicine in their joint efforts to expand clinical trial participation in our state for the benefit of patients in Indiana and around the globe.'
'The Lechleiter and Tobias families could have made this gift anywhere in the world. Choosing IU Health and IU School of Medicine demonstrates immense trust in our researchers and caregivers,' IU Health President and CEO Dennis Murphy said. 'Thanks to this commitment, our patients will get early access to life-saving treatments and The Institute for Clinical Innovation will become a destination for leading-edge healthcare.'
IU Health's $2.31 billion hospital complex, which will replace the aging IU Health Methodist Hospital, is expected to open in late 2027.
IU Health hospital development: 'If we only build a great hospital, we will have failed:' IU Health project spurs new group
Alysa Guffey covers business and development for IndyStar. Contact her at amguffey@gannett.com.
This article originally appeared on Indianapolis Star: Former Lilly executives donate $20 million for IU clinical institute
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Trump team set to destroy $12m worth of HIV drugs and contraceptives that were bought before closing USAID
Roughly $12 million worth of HIV-prevention drugs and contraceptives purchased by the U.S. Agency for International Development will likely be destroyed after President Donald Trump dismantled the organization, according to a report. These drugs have been sitting in distribution centers in Belgium and the UAE since January, when Trump ended the agency's spending, The Washington Post reported. Now, negotiators have been instructed to sell the drugs or else they'll be thrown out, according to the outlet. 'The mandate that [the USAID negotiator] has been given is 'get us money for it, and if you can't do that, we're just going to trash it,'' someone with knowledge of the situation told the Post. These supplies include more than 26 million condoms, 2 million doses of injectable birth control, millions of packages of oral birth control, hundreds of thousands of implantable contraceptive devices, and over 50,000 vials of a drug that prevents HIV contraction, the Post reports. Some of these supplies were earmarked for 18 countries, meaning those governments may never get the aid even though it was already purchased, according to the Post. When contacted for comment, a senior State Department official told The Independent that the Post has 'once again delivered fake news' and the 'story is full of inaccuracies.' Atul Gawande, a former assistant USAID administrator, told the Post the potential destruction of these drugs is 'inconceivable.' Meanwhile, Former USAID head Andrew Natsios called the decision 'nuts.' 'At this point, just give it away instead of destroying it, for heaven's sakes,' he told the Post. Trump cut off USAID funds in January, saying the organization that provides humanitarian aid abroad is 'not aligned with American interests.' The Trump administration is also poised to ask Congress for $8.3 billion in cuts to foreign aid efforts, which range from climate work to LGBTQ+ programs, The Independent previously reported. The decision has derailed the projected end of the AIDS pandemic and means the number of AIDS-related deaths could jump from six million to 10 million in the next five years unless aid is reinstated, The Independent previously reported. Data projections indicate there will be 3.4 million more orphans who have lost at least one parent to AIDS, and 600,000 more newborns could contract HIV by 2030. 'All the gains that we've seen over the last 20 years will start being steadily reversed,' Professor Francois Venter, a leading HIV doctor at the University of Witwatersrand in Johannesburg, previously told The Independent. Hadja, a 27-year-old mother of three in Uganda, previously told The Independent she has lost access to lifesaving medication since Trump effectively shut down USAID. 'Our lives depend on medicine – without it, our lives are shortened,' she said. 'If I die, my children will suffer.'
Washington Post
13 hours ago
- Washington Post
Tracking Trump: Musk calls for Trump impeachment; a wrongly deported man is returned; U.S. and China resume trade talks; and more
Trump and Elon Musk turned up the heat on their feud. The Trump administration returns a wrongly deported man. U.S. and China agreed to resume trade negotiation meetings. $12 million in HIV medication and other foreign aid may be destroyed. A judge ordered the restoration of AmeriCorps programs in 24 states. European nations fear losing access to U.S. intelligence. Trump helped get Pete Rose's baseball ban overturned. In case you missed it … Colleagues of former Biden White House press secretary Karine Jean-Pierre aren't holding their punches when it comes to Jean-Pierre's upcoming book on her decision to leave the Democratic Party. Also: 23andMe bankruptcy proceedings have left the fate of millions of people's genetic data up in the air. Want to stay on top of President Trump's second term? Sign up for the newsletter to get the top stories every weeknight.
Yahoo
16 hours ago
- Yahoo
Prediction: Eli Lilly Will Reach a $1 Trillion Valuation by 2027
Eli Lilly has been experiencing strong growth lately due to its impressive GLP-1 drugs. It could rake in a couple more approvals within the next year. The stock has been sliding this year, and that has made its valuation look much more appealing. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the world, with a market cap of more than $650 billion. But there's still much more growth on the horizon for the business in the years ahead. Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe that its shares have peaked. Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Eli Lilly's stock has surged close to 400% in five years. But for it to get going again and start rallying, it'll likely need a catalyst and a reason for growth investors to rally around its business. The good news is that it may not be too long before that happens. A big reason for the company's growth is the hype and excitement surrounding its GLP-1 treatments, Zepbound (approved for weight loss) and Mounjaro (approved for diabetes). These blockbuster drugs have been generating billions in revenue and have bolstered the company's growth rate in recent quarters. The drug that you should keep an eye on moving forward, however, is orforglipron. Unlike Zepbound and Mounjaro, which are injections, orforglipron is a pill that can be a more attractive option for patients looking to lose weight or to bring down their glucose levels. Eli Lilly expects that the drug could obtain approval from regulators by as early as next year. Clinical trials thus far have been encouraging, with the drug showing it can help people lose around 15% of their body weight. The company is also working on another injectable treatment, retatrutide, which has the potential to be its best weight loss treatment yet. In a recent clinical trial, patients using the drug lost more than 24% of their body weight. With not one but two exciting weight loss drugs that may potentially obtain approval in the near future, it may not be too long before this healthcare stock gets going again. It wasn't all that long ago that Eli Lilly's stock looked incredibly expensive, trading at well over 100 times its trailing earnings. But as the stock has fallen this year and as its earnings have grown, its valuation has become much more attractive. While its price-to-earnings (P/E) multiple is still significant at 60, based on analyst estimates, its forward P/E multiple is just 34. And when you look at its price-to-earnings growth (PEG) ratio, which sits at around 1.1, that suggests the stock may even be cheap given the future growth the business may experience. For PEG, anything below 1 indicates great value for growth investors. However, Eli Lilly is arguably worth a premium, which is why I don't think these multiples will stay as low as they are for long. The overall healthcare sector has been struggling this year. The Health Care Select Sector SPDR Fund has declined by more than 3% since January. The market appears to be concerned over healthcare spending cuts and how they may affect stocks across the entire sector. But for Eli Lilly, one of the top healthcare companies in the world -- which grew its sales by 32% last year to $45 billion and still looks unstoppable -- the stock should be doing much better than it is. For Eli Lilly to reach a $1 trillion market cap within the next couple of years, it would need to rise by more than 50% from where it is today. I think that's possible as its earnings continue to grow, and especially if you factor in that it's underperforming this year and that there could be multiple approvals coming its way in the not-too-distant future. This is a top growth stock to own, and now that its valuation has come down, it could be a remarkable investment to load up on. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor's total average return is 987% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Prediction: Eli Lilly Will Reach a $1 Trillion Valuation by 2027 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
